Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
294 Results for "
Dermatitis
" in MedChemExpress (MCE) Product Catalog:
Products (294)
294 Results for "Dermatitis" in MCE Product Catalog:
Target:
Research Areas:
Pramocaine (Pramoxine) hydrochloride (Standard) is the analytical standard of Pramocaine hydrochloride (HY-B1319). This product is intended for research and analytical applications. Pramocaine hydrochloride is a topical surface anesthetic and antipruritic agent. Pramocaine hydrochloride reversibly inhibits voltage-gated sodium channel, reduces transmembrane permeability of sodium ions, stabilizes cell membranes, prevents depolarization, blocks action potential conduction, and inhibits peripheral slow C-fiber pathways associated with pain, pruritus and thermoception. Pramocaine hydrochloride can be used in research related to chronic pruritus, renal pruritus, atopic dermatitis, xerotic pruritus, uremic pruritus, and cutaneous hyperalgesia/pain .
Cat. No.: HY-N8593S
CAS No.: 164858-54-2
Cat. No.: HY-P991598
CAS No.: 2304625-87-2
Synonyms: MOR12743; MOR03207
Target:
Research Areas:
Cat. No.: HY-111167
CAS No.: 906673-33-4
Research Areas:
AN-2898 is a selective PDE4 inhibitor with IC50 of 0.027 μM over other phosphodiesterase enzymes, such as PDE1A, PDE2A and PDE3A. AN-2898 also potently inhibits PDE4 subtypes (PDE4B1, PDE4A1A and PDE4D2). AN-2898 significantly inhibits the production of TNF-α, IL-2, IFN-γ, IL-5 and IL-10. AN-2898 can be used for mild to moderate atopic dermatitis (AD) and psoriasis research .
Cat. No.: HY-176520
CAS No.: 2815361-45-4
Target:
Research Areas:
PDE4-IN-29 (Compound 55) is an orally active and selective PDE4 inhibitor (including subtypes such as PDE4A1, PDE4B2, PDE4D3) with IC50s of <5 nM against PDE4D3. PDE4-IN-29 inhibits the degradation of cyclic adenosine monophosphate (cAMP), increases intracellular cAMP levels, suppressing the release of inflammatory factors such as TNF-α. PDE4-IN-29 is promising for research of inflammatory diseases including psoriasis, atopic dermatitis, and chronic obstructive pulmonary disease .
Cat. No.: HY-B1319S1
Synonyms: Pramoxine-d9 hydrochloride
Cat. No.: HY-P5255
CAS No.: 466691-40-7
Target:
Research Areas:
Cat. No.: HY-P992034
Synonyms: PR001
Target:
Research Areas:
APG808 (PR001) is an anti-human IL-4Rα monoclonal antibody. APG808 binds to IL-4Rα, prevents IL-13Rα1/IL-4Rα heterodimer formation, and disrupts IL-13 and IL-4 mediated signaling. APG808 ablates Fc and complement effector functions. APG808 can be used for the research of chronic obstructive pulmonary disease, asthma, atopic dermatitis .
Cat. No.: HY-P992521
Target:
Research Areas:
HB-0043 is a IL-17A and IL-36R antagonist. HB-0043 blocks IL-17A- and IL-36R-mediated signaling pathways, inhibits the production of inflammatory cytokines, and reduces the secretion of pro-inflammatory cytokines IL-6 and IL-8. HB-0043 alleviates skin thickening and inflammatory responses in oxazolone-induced and Imiquimod (HY-B0180)-induced skin reaction mouse models. HB-0043 is applicable for the research of atopic dermatitis and psoriasis .
Cat. No.: HY-169864
CAS No.: 1137536-21-0
Target:
Research Areas:
KRO-105714 is the antagonist for sphingosine phosphocholine receptor (SPC Receptor) and sphingosine-1-phosphate receptor 1 (S1P1 Receptor) (IC50=79.2 nM). KRO-105714 inhibits SPC-induced proliferation of NIH3T3 (IC50=5.6 nM), inhibits SPC-induced cell migration (IC50=0.59 μM) and tube formation in HUVECs. KRO-105714 inhibits SPC-induced generation of IL-4 and IL-5, exhibits anti-inflammtory efficacy in mouse atopic dermatitis models .
Cat. No.: HY-P992132
CAS No.: 3057433-10-7
Synonyms: STAR-0310
Research Areas:
Cat. No.: HY-158990
CAS No.: 2883669-12-1
Research Areas:
GE1111 is a MRGPRX2 antagonist (IC50 = 9.4 μM). GE1111 inhibits MRGPRX2/MRGPRB2-mediated mast cell activation. GE1111 reduces the expressions of TSLP, IL-13, MCP-1, TNF-α, IL-1β and periostin, maintains the expression levels of claudin 1 and involucrin, restores the phagocytic activity of macrophages, and attenuates the activation of STIM1 and phosphorylated AKT. GE1111 exerts anti-inflammatory and anti-allergic effects in multiple animal models. GE1111 is applicable to the research related to rosacea, atopic dermatitis and ulcerative colitis .
Cat. No.: HY-187958
CAS No.: 91837-56-8
Target:
Research Areas:
PO-322 is a selective SGK1 inhibitor with an IC50 of 54 nM. PO-322 reduces NDRG1 phosphorylation through inhibition of SGK1. PO-322 inhibits T cell proliferation and the production of IL-17, IFN-γ, and IL-6, accompanied by upregulated phosphorylation of p70S6K and STAT5. PO-322 exhibits immunosuppressive activity both in vitro and in vivo, and attenuates DNFB-induced delayed-type hypersensitivity and Imiquimod (HY-B0180)-induced psoriasis-like dermatitis. PO-322 is useful for research related to autoimmune diseases and psoriasis .
Cat. No.: HY-P990090
CAS No.: 2648260-80-2
Synonyms: CBP-201
Target:
Research Areas:
Cat. No.: HY-17609S
Synonyms: CR-845-d5; FE-202845-d5
Cat. No.: HY-17609S1
Synonyms: CR-845-d5 hydrochloride; FE-202845-d5 hydrochloride
Cat. No.: HY-19205A
CAS No.: 193739-23-0
Synonyms: LDP-392
Research Areas:
CMI-392 (LDP-392) is an orally active dual 5-lipoxygenase inhibitor and platelet-activating factor receptor (PAFR) antagonist, with an IC50 of 10 nM for human PAF receptor and an IC50 of 100 nM for rat 5-lipoxygenase. CMI-392 blocks PAF receptor binding, inhibits leukotriene synthesis, attenuates PAF-induced hemoconcentration, and suppresses arachidonic acid- and TPA-induced ear swelling in mice. CMI-392 reduces inflammatory cell infiltration, decreases MPO levels, alleviates ocular inflammation, and improves dextran sulfate sodium-induced colitis. CMI-392 can be used in the research of inflammatory and immune-related diseases such as colitis and atopic dermatitis .
Cat. No.: HY-P990093
CAS No.: 2734715-10-5
Synonyms: CM310
Target:
Research Areas:
Research Areas:
JTE-907 is a selective and orally active cannabinoid CB2 receptor inverse agonist and exerts anti-inflammatory effects. JTE-907 upregulates IL-6, MCP-1, IL-1β, VEGF, ANGPTL4, and TRPV1 in mature adipocytes. JTE-907 downregulates CB1, MCP-1, and IL-1β in preadipocytes. JTE-907 inhibits ear swelling in mice. JTE-907 reverses the protective effects of CB2 agonists and Anandamide (HY-10863) against cytokine-evoked colonic mucosal damage. JTE-907 can be used for the research of allergic dermatitis, obesity, and colitis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
